Collegium Pharmaceutical (COLL) reported $177.76 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 22.7%. EPS of $1.49 for the same period compares to $1.45 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $172.45 million, representing a surprise of +3.08%. The company delivered an EPS surprise of +4.20%, with the consensus EPS estimate being $1.43.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total product revenues- Belbuca: $51.66 million versus $53.86 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2% change.
- Total product revenues- Xtampza ER: $47.64 million versus the three-analyst average estimate of $46.49 million. The reported number represents a year-over-year change of +4%.
- Total product revenues- Jornay PM: $28.54 million compared to the $28.50 million average estimate based on three analysts.
- Total product revenues- Nucynta: $47.10 million compared to the $42.13 million average estimate based on three analysts. The reported number represents a change of +4.3% year over year.
- Total product revenues- Symproic: $2.82 million versus the three-analyst average estimate of $3.25 million. The reported number represents a year-over-year change of -14.7%.
View all Key Company Metrics for Collegium Pharmaceutical here>>>
Shares of Collegium Pharmaceutical have returned +2.6% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
